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Introduction
Rheumatoid arthritis (RA) is one of the most common sys-
temic autoimmune diseases in which an imbalance between 
pro-inflammatory and anti-inflammatory subsets of T lym-
phocytes seems to occur [1].
The chronic synovial damage and the resulting progres-
sive destruction of cartilage and joints are mainly mediated 
by pro-inflammatory cytokines released by Th1 and Th17 
subsets of T effector cells [2].
A defect in Treg functions has been also described in RA 
[3]. Treg cells inhibit proliferation and cytokine produc-
tion of conventional T cells in physiologic conditions, and 
their deficiency seems to be associated with autoimmunity 
[4]. Treg cells control the occurrence of abnormal immune 
responses not only through the down-regulation of co-stim-
ulatory molecules but also through the secretion of suppres-
sive cytokines such as TGF-β, IL-10 and IL-35. Recently, it 
has been also demonstrated that Treg may potentially pro-
duce pro-inflammatory cytokines, such as IL-17, particularly 
when in vivo exposed to an inflammatory environment [5, 6]. 
Conventional Treg are usually identified as CD4+/Foxp3+/
CD25+/IL-10+ cells. Recently, however, a new subset of T 
cells producing both IL-17 and IL-10 and displaying regu-
latory function (Th17+IL-10+ cells) has been described [5]. 
Data on Th17 IL10+ in RA are, until now, lacking.
It is widely accepted that the therapeutic goal for 
patients with RA is the achievement of clinical remis-
sion and several evidences suggest that T cell subsets may 
be influenced by anti-RA agents. Studies evaluating the 
changes in T cell subset distribution in response to conven-
tional disease modifying anti-rheumatic drugs (DMARD) 
are, however, limited at present.
The aim of the present study was to evaluate the in vitro 
effect of methotrexate (MTX) and/or methylprednisolone 
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(MP) on the percentage of Th17 and Treg cell subsets. Here, 
we demonstrate that MTX and/or MP are capable to modify 
in vitro the imbalance of Th17/Treg in the peripheral blood 
of patient with early RA and suggest a possible regulatory 
function of Th17 cells through the expression of IL-10.
Materials and methods
Subjects
Blood from 15 RA patients and 10 healthy donors was 
obtained for this study. Gender and clinical data of all sub-
jects are shown in Table 1. Patients fulfill the 1987 crite-
ria of the American College of Rheumatology for RA. Ten 
of the patients, classified as having an early RA (ERA), 
were DMARDs naïve and did not assume prednisone or 
equivalents since last 4 weeks before blood collection. 
Five patients had a long-standing disease (LRA). All of 
them exhibited insufficient response to leflunomide or sala-
zopyrin in monotherapy and were MTX intolerants and 
were taking glucocorticoids <10 mg per day. Patients and 
healthy donors signed the informed consent, as suggested 
by the bioethical committee of Paolo Giaccone University 
Hospital, Palermo.
Isolation, cell culture and intracellular staining
Peripheral blood mononuclear cells (PBMCs) were 
obtained as previously described [7]. Part of recovered cells 
(1 × 106/ml) were in vitro cultured with PMA (50 ng/ml) 
and ionomycin (1 µg/ml) (Sigma St. Louis, MO) for 24 h; 
the remaining cells were incubated with MTX (10 µM), 
MP alone (1 µg/ml) or MTX + MP at 37 °C in 5 % CO2. 
After 2 h of incubation, Brefeldin A (10 µg/ml; Sigma St. 
Louis, MO) was added, and after 24 h of incubation, cells 
were collected and stained with the following monoclonal 
antibodies (mAb): anti-human CD4-PE-Cy5.5 (BD Bio-
sciences, San Josè, CA), anti-human IL-17-APC (R&D 
system, Minneapolis, MN), anti-human CD25-FITC (BD 
Biosciences, San Josè, CA) and anti-human IL-10-PE (BD 
Biosciences, San Josè, CA).
Isotype-matched irrelevant antibodies were used as 
a negative control. Cells were incubated with mAbs for 
30 min on ice and washed twice in PBS, containing 0.1 % 
(w/v) NaN3. After surface staining, the cells were fixed 
with 1 % (w/v) paraformaldehyde (Sigma) for 30 min at 
4 °C and then were permeabilized with a permeabilization 
solution (BD Biosciences) for 10 min at room temperature 
and stained with antibodies for intracellular antigens for 30 
min at 4 °C. Four color flow cytometry analysis was per-
formed using a FACSCalibur (BD Biosciences). At least 
50,000 cells (events), gated on lymphocytes region, were 
acquired for each sample.
Statistical analysis
Statistical analysis of quantitative variables was per-
formed using the Mann–Whitney rank-sum test. Data are 
expressed as mean ± SEM. p values < 0.05 were consid-
ered significant.
Results
At baseline, the percentage of Th17 effector T cells was 
found to be significantly higher in the peripheral blood of 
both ERA (3.7 ± 0.4) and LRA (4 ± 0.5) patients when 
compared to those of control subjects (1 ± 0.07), no dif-
ference being present between ERA and LRA (Fig. 1a, 
f). As shown in Fig. 1d, the expression of RORγt did not 
significantly differ between ERA (2.5 ± 0.4) and LRA 
(3 ± 0.5). The percentages of the conventional Treg iden-
tified as CD4+/CD25+/IL-10+/IL-17− T cells were sig-
nificantly reduced in RA patients (ERA 1 ± 0.03; LRA 
0.8 ± 0.02) compared to controls (2.3 ± 0.6) (Fig. 1b, g). 
The same reduction was found among FoxP3+ cells in ERA 
(0.8 ± 0.02) and LRA (0.5 ± 0.05). CD4+IL-17+IL-10+ T 
Table 1  Baseline characteristics of RA patients and control subjects
Controls (N = 10) ERA patients (N = 10) LRA patients (N = 5)
Age (years) (SD) 48 (3) 44 (3) 49 (2)
Female (%) 100 80 100
Disease duration (years), median (SD) NA <1 (0.6) 7.7 (2.3)
DAS-28 CRP, median (SD) NA 6 (1.6) 5.9 (1.4)
HAQ, median (SD) NA 2 (0.6) 3 (0.7)
CRP (mg/l), median (SD) NA 5 (1.9) 5 (1.9)
ESR (mm/h), median (SD) NA 57 (22) 47 (18)
RF, frequency, conc. (UI/l) (range) NA 72 [87 (32–210)] 65 [80 (30–222)]
Anti-CCP, frequency, conc. (UI/l) (range) NA 86 [130 (54–355)] 80 [135 (50–398)]
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cells were not detected in the PBMC from patients but were 
present in healthy subjects (1 ± 0.05) (Fig. 1c, f).
After incubation with MTX, a significant reduction in the 
percentage of Th17 effector cells (1.9 ± 0.03) was observed 
in the PBMC from ERA patients (Fig. 2a, d) together with 
a significant increase in Treg cells (2.27 ± 0.15) (Fig. 2b, 
e). Moreover, the percentage of RORγt positive cells was 
also significantly reduced in ERA (1.7 ± 0.2) compared to 
LRA patients (2.7 ± 0.3). A massive increase in CD4+IL-
17+IL-10+ T cells (1.1 ± 0.02) after incubation with 
MTX was also observed (Fig. 2c, d). Interestingly, these 
cells expressed both RORγt and FoxP3 differently from 
conventional Tregs that do not express RORγt (CD4+IL-
17+IL-10+ RORγt+ FoxP3+ 0.96 ± 0.04).
Incubation of PBMC from patients with LRA deter-
mined a less evident increase in Treg cells (1.76 ± 0.1) 
(Fig. 2b), a less consistent expansion of CD4+IL-17+IL-10+ 
T cells (0.25 ± 0.09) (Fig. 2c) and minor significant reduc-
tion in Th17 cells (3 ± 0.1) (Fig. 2a). Similar results were 
obtained by adding MP to PBMC culture both in ERA (Th17 
1.8 ± 0.16, Treg 2.5 ± 0.4, CD4+IL-17+IL-10+ T cells 
0.6 ± 0.23) and LRA (Th17 3.2 ± 0.8, Treg 2.1 ± 0.07, 
CD4+IL-17+IL-10+ T cells 0.4 ± 0.06) and in controls 
(Th17 0.6 ± 0.03, Treg 3.2 ± 0.05, CD4+IL-17+IL-10+ T 
cells 0.9 ± 0.07) (Fig. 2). The addition of both MTX and MP 
determined a significant enhancement of Treg and CD4+IL-
17+IL-10+ T cells in ERA patients (Treg 3 ± 0.2, CD4+IL-
17+IL-10+ T cells 1 ± 0.08) but not in LRA (Treg 3.3 ± 0.5, 
CD4+IL-17+IL-10+ T cells 1 ± 0.06) (Fig. 2b, c).
Discussion
Our results show that the in vitro addition of MTX and/or 
MP in PBMC cultures from patients with ERA is capable 
to modify the imbalance of Th17/Treg and suggest a possi-
ble regulatory function of Th17 cells trough the expression 
of IL-10, being the differences observed in LRA probably 
Fig. 1  Ex vivo percentages of Th17, Treg and Th17-IL-10+ subsets. 
a Mean percentage of Th17 cell subset in peripheral blood of ERA 
and LRA patients and controls. b Mean percentage of Treg cell subset 
in peripheral blood of ERA and LRA patients and controls. c Mean 
percentage of Th17-IL-10+ cell subset in peripheral blood of ERA 
and LRA patients and controls. d Mean percentage of RORγt+ cells 
in peripheral blood of ERA and LRA patients and controls. e Mean 
percentage of FoxP3+ cells in peripheral blood of ERA and LRA 
patients and controls. f, g Dot-plot analysis of Th17, Treg and Th17-
IL-10+ from a representative ERA patients and a healthy subject
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due to the difference stage of disease and/or lower number 
of patients studied and/or prior therapy and/or indicating an 
unresponsive status to MTX.
The paradigm of a Th1/Th2 imbalance in RA was 
refined recently by the identification of Th17 and Treg lym-
phocyte subsets [4, 8, 9].
It is well known that Th17 cells contribute to tissue 
damage in RA [8]. Th17 cells act promoting tissue inflam-
mation by the secretion of IL-17 that stimulates synovial 
fibroblast to release several mediators of joint inflamma-
tion including IL-6, IL-8, GM-CSF and PGE2 [10]. Treg 
function is known to be reduced or absent during RA flares 
and restored by several targeted treatments such as TNF-
α antagonists, anti-IL6R antibodies and rituximab [3, 11]. 
No data are present in the literature concerning the effect 
of MTX alone or in combination with MP on Th17, on 
conventional Treg cells and in particular on the recently 
described subset of IL-17+ IL-10+ CD4 T lymphocytes.
Recently, Scottà et al. [6] described a subpopulation of 
conventional Treg producing both IL-10 and IL-17 and 
demonstrated that in vitro pre-treatment with rapamycin or 
rapamycin plus retinoic acid completely prevented IL-17 
and IFN-γ production, while untreated or retinoic acid-
treated Tregs produced both cytokines.
The IL-10 expression among Th17 cell population was 
also evaluated. Brunsing and Prossnitz [12] demonstrated 
that an agonist of the membrane-bound G-protein-coupled 
estrogen receptor GPER, namely G-1, is capable to elicit 
IL-10 expression in Th17-polarized cells, increasing the 
number of IL-10+ and IL-10+ IL-17A+ cells via de novo 
induction of IL-10. G-1 appeared to act directly on CD4+ 
T cells, providing the first example of a synthetic small 
molecule capable of eliciting IL-10 expression in Th17 or 
hybrid T cell populations [12]. In this case, this subset of 
lymphocytes could be considered as a conventional Treg 
subpopulation able to produce effector cytokines such as 
Fig. 2  In vitro effect of MTX, MP and MTX + MP treatment on 
PBMCs obtained from ERA and LRA patients and controls. a Mean 
percentage of Th17 cell subset after in vitro treatment with MTX, MP 
and MTX + MP of PBMCs from ERA and LRA patients and con-
trols b Mean percentage of Treg cell subset after in vitro treatment 
with MTX, MP and MTX + MP of PBMCs from ERA and LRA 
patients and controls. c Mean percentage of Th17-IL-10+ cell subset 
after in vitro treatment with MTX, MP and MTX + MP of PBMCs 
from ERA and LRA patients and controls. d, e Dot-plot analysis of 
Th17, Treg and Th17-IL-10+ from a representative ERA patients 
after pBMCs incubation with several drugs. *p < 0.05
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IL-17 or a Th17 subset showing regulatory functions pro-
ducing IL-10.
According to the results of our study, the addition of 
MTX and MP on PBMCs from patients with early RA was 
able of favoring the secretion of both cytokines in CD4+ 
cells as well as the retinoic acid or promoting the differen-
tiation of CD4 T cells in the regulatory subsets as well as 
G-1.
In this preliminary study, we demonstrated that, at least 
in vitro, MTX and MP are capable to regulate the Th17 
effector functions and speculate that these molecules are 
capable to induce proliferation of CD4+/IL-17+/IL-10+ 
lymphocytes. A recent paper published by Szalay et al. 
[13] provides a longitudinal follow-up of the prevalence of 
CD4+ cell subsets during different RA treatment protocols 
demonstrating, in according with our results, that the pro-
inflammatory immune phenotype Th17 is normalized under 
steroid and MTX treatment in early RA. The imbalance 
between Th17/Treg is a key mechanism in the pathogenesis 
and progression of the disease. In this regard, it appears to 
be necessary to better characterize the role of therapy on 
this subset in in vivo studies.
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